ALLK Allakos Inc.

35.16
-0.8  -2%
Previous Close 35.96
Open 36.03
Price To Book 9.04
Market Cap 1,516,447,478
Shares 43,123,773
Volume 9,011
Short Ratio
Av. Daily Volume 329,817

NewsSee all news

  1. Ohio Capital Fund's management firm seeks 3-year extension, raise
  2. Allakos Reports First Quarter 2019 Financial Results
  3. Allakos Announces Positive Results with AK002 in Patients with Severe Allergic Conjunctivitis
  4. Is Allakos Inc. (ALLK) A Good Stock To Buy?
  5. Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data May 7, 2019 noted a 78% median improvement in ocular symptoms
AK002
Severe Allergic Conjunctivitis
Phase 1 data released February 19, 2019.
AK002
Indolent Systemic Mastocytosis
Phase 2 additional data released February 11, 2019. 9% UAS7 complete responder rate.
AK002
Chronic Urticaria
Phase 2 top-line data due mid-2019.
AK002
Eosinophilic Gastritis

Latest News

  1. Ohio Capital Fund's management firm seeks 3-year extension, raise
  2. Allakos Reports First Quarter 2019 Financial Results
  3. Allakos Announces Positive Results with AK002 in Patients with Severe Allergic Conjunctivitis
  4. Is Allakos Inc. (ALLK) A Good Stock To Buy?
  5. Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights
  6. State-backed VC vehicle managers aren't worried about dipping into tax credits – here's why
  7. Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis
  8. Allakos Enters Oversold Territory
  9. Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts
  10. Allakos to Host Investor Day on February 19 in New York City
  11. Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism
  12. Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients
  13. Here are the winners and losers from Bay Area's IPO class of 2018
  14. 5 Best-Performing IPOs of 2018
  15. Allakos (ALLK) Catches Eye: Stock Jumps 6.5%
  16. Here's how much better insiders have profited from this year's IPO boom
  17. Has Allakos Inc (NASDAQ:ALLK) Got Enough Cash?
  18. New Research Coverage Highlights TheStreet, EVO Payments, Odyssey Marine Exploration, Allakos, SORL Auto Parts, and SPAR Group — Consolidated Revenues, Company Growth, and Expectations for 2018
  19. Allakos Announces Clinical Update and Third Quarter 2018 Financial Results